BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 27885879)

  • 1. A high preoperative carbohydrate antigen 19-9 level is a risk factor for recurrence in stage II colorectal cancer.
    Nozawa H; Ishihara S; Kawai K; Hata K; Kiyomatsu T; Tanaka T; Nishikawa T; Otani K; Yasuda K; Sasaki K; Murono K; Watanabe T
    Acta Oncol; 2017 May; 56(5):634-638. PubMed ID: 27885879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
    Stanisavljević L; Myklebust MP; Leh S; Dahl O
    Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of carcinoembryonic antigen and carbohydrate antigen 19-9 in stage IV colorectal cancer patients after R0 resection.
    Abe S; Kawai K; Ishihara S; Nozawa H; Hata K; Kiyomatsu T; Tanaka T; Watanabe T
    J Surg Res; 2016 Oct; 205(2):384-392. PubMed ID: 27664887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative Neutrophil-to-Lymphocyte Ratio is a Better Prognostic Serum Biomarker than Platelet-to-Lymphocyte Ratio in Patients Undergoing Resection for Nonmetastatic Colorectal Cancer.
    Choi WJ; Cleghorn MC; Jiang H; Jackson TD; Okrainec A; Quereshy FA
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S603-13. PubMed ID: 25900206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Significance of Preoperative Serum Carbohydrate Antigen 19-9 in Patients With Stage IV Colorectal Cancer.
    Ozawa T; Ishihara S; Kawai K; Nozawa H; Yamaguchi H; Kitayama J; Watanabe T
    Clin Colorectal Cancer; 2016 Dec; 15(4):e157-e163. PubMed ID: 27245559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for recurrence in stage II/III colorectal cancer patients treated with curative surgery: The impact of postoperative tumor markers and an infiltrative growth pattern.
    Tokodai K; Narimatsu H; Nishida A; Takaya K; Hara Y; Kawagishi N; Hashizume E; Ohuchi N
    J Surg Oncol; 2016 Sep; 114(3):368-74. PubMed ID: 27264681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefit of Adjuvant Chemotherapy After Curative Resection of Lung Metastasis in Colorectal Cancer.
    Park HS; Jung M; Shin SJ; Heo SJ; Kim CG; Lee MG; Beom SH; Lee CY; Lee JG; Kim DJ; Ahn JB
    Ann Surg Oncol; 2016 Mar; 23(3):928-35. PubMed ID: 26514121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphocyte-to-monocyte ratio combined with CA19-9 for predicting postoperative recurrence of colorectal cancer in patients with diabetes.
    Yu D; An G; Yao J
    J Clin Lab Anal; 2021 Sep; 35(9):e23944. PubMed ID: 34418175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy.
    Kim JE; Hong YS; Kim HJ; Kim KP; Lee JL; Park SJ; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Hoon KJ; Kim TW
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S630-7. PubMed ID: 26271397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of predictive biomarkers for therapeutical strategies in colorectal cancer.
    Gasser M; Gerstlauer C; Grimm M; Bueter M; Lebedeva T; Lutz J; Maeder U; Ribas C; Ribas C; Nichiporuk E; Thalheimer A; Heemann U; Thiede A; Meyer D; Waaga-Gasser AM
    Ann Surg Oncol; 2007 Apr; 14(4):1272-84. PubMed ID: 17211733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-chemotherapeutic CEA and CA19-9 are prognostic factors in patients with colorectal liver metastases treated with hepatic resection after oxaliplatin-based chemotherapy.
    Sakamoto Y; Miyamoto Y; Beppu T; Nitta H; Imai K; Hayashi H; Baba Y; Yoshida N; Chikamoto A; Baba H
    Anticancer Res; 2015 Apr; 35(4):2359-68. PubMed ID: 25862901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear Notch3 expression is associated with tumor recurrence in patients with stage II and III colorectal cancer.
    Ozawa T; Kazama S; Akiyoshi T; Murono K; Yoneyama S; Tanaka T; Tanaka J; Kiyomatsu T; Kawai K; Nozawa H; Kanazawa T; Yamaguchi H; Ishihara S; Sunami E; Kitayama J; Morikawa T; Fukayama M; Watanabe T
    Ann Surg Oncol; 2014 Aug; 21(8):2650-8. PubMed ID: 24728738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative serum carcinoembryonic antigen, carbohydrate antigen19-9 and carbohydrate antigen 125 as prognostic factors for recurrence-free survival in colorectal cancer.
    Yang XQ; Chen C; Wang FB; Peng CW; Li Y
    Asian Pac J Cancer Prev; 2011; 12(5):1251-6. PubMed ID: 21875276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
    Ben-Aharon I; Goshen-Lago T; Sternschuss M; Morgenstern S; Geva R; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Shulman K; Mishaeli M; Man S; Liebermann N; Soussan-Gutman L; Brenner B
    Oncologist; 2019 Aug; 24(8):e696-e701. PubMed ID: 30755502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative Lower Body Mass Index Correlates with Poorer Prognosis in Patients Undergoing Curative Laparoscopic Surgery for Colorectal Cancer.
    Uratani R; Toiyama Y; Shimura T; Mori K; Fujikawa H; Hiro J; Ohi M; Inoue Y; Tanaka K; Araki T; Mohri Y; Kusunoki M
    Anticancer Res; 2015 Oct; 35(10):5639-48. PubMed ID: 26408737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and Oncologic Significance of Perineural Invasion in Sporadic Colorectal Cancer.
    Alotaibi AM; Lee JL; Kim J; Lim SB; Yu CS; Kim TW; Kim JH; Kim JC
    Ann Surg Oncol; 2017 Jun; 24(6):1626-1634. PubMed ID: 28070726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor budding is an independent predictor of outcome in AJCC/UICC stage II colorectal cancer.
    Betge J; Kornprat P; Pollheimer MJ; Lindtner RA; Schlemmer A; Rehak P; Vieth M; Langner C
    Ann Surg Oncol; 2012 Nov; 19(12):3706-12. PubMed ID: 22669453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological Factors Associated with Recurrence and Prognosis after R0 Resection for Stage IV Colorectal Cancer with Peritoneal Metastasis.
    Sato H; Kotake K; Sugihara K; Takahashi H; Maeda K; Uyama I;
    Dig Surg; 2016; 33(5):382-91. PubMed ID: 27119565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The preoperative platelet to lymphocyte ratio is a prognostic marker in patients with stage II colorectal cancer.
    Ozawa T; Ishihara S; Nishikawa T; Tanaka T; Tanaka J; Kiyomatsu T; Hata K; Kawai K; Nozawa H; Kazama S; Yamaguchi H; Sunami E; Kitayama J; Watanabe T
    Int J Colorectal Dis; 2015 Sep; 30(9):1165-71. PubMed ID: 26049902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.